MedTrace Logo

Depression and Fatigue in MS Patients Treated With Betaferon.

NCT01354665 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 567

Last updated 2015-01-21

No results posted yet for this study

Summary

This study aims to evaluate the occurence and severity of fatigue and depression in multiple sclerosis patients and the impact of Betaferon treatment on symptoms alterations.

The study is conducted in routine practice setting hence no interference with standard care takes place.

Pharmacologic treatments of MS-fatigue and depression will also be recorded.

Conditions

Interventions

BIOLOGICAL

Interferon beta-1b (Betaferon, BAY86-5046)

Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under routine practice setting.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Poland

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01354665 on ClinicalTrials.gov